SG11201908131RA - Benzazepine compounds, conjugates, and uses thereof - Google Patents
Benzazepine compounds, conjugates, and uses thereofInfo
- Publication number
- SG11201908131RA SG11201908131RA SG11201908131RA SG11201908131RA SG 11201908131R A SG11201908131R A SG 11201908131RA SG 11201908131R A SG11201908131R A SG 11201908131RA SG 11201908131R A SG11201908131R A SG 11201908131RA
- Authority
- SG
- Singapore
- Prior art keywords
- her2
- conjugate
- international
- suite
- washington
- Prior art date
Links
- 150000008038 benzoazepines Chemical class 0.000 title abstract 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 10
- 101150013553 CD40 gene Proteins 0.000 abstract 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 abstract 1
- 241000409201 Luina Species 0.000 abstract 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471886P | 2017-03-15 | 2017-03-15 | |
US201762573630P | 2017-10-17 | 2017-10-17 | |
US201862622780P | 2018-01-26 | 2018-01-26 | |
PCT/US2018/022510 WO2018170179A1 (fr) | 2017-03-15 | 2018-03-14 | Composés de benzazépine, conjugués et utilisations associées |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908131RA true SG11201908131RA (en) | 2019-10-30 |
Family
ID=63523998
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908131R SG11201908131RA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110184X SG10202110184XA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110183V SG10202110183VA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110182P SG10202110182PA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110181R SG10202110181RA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110184X SG10202110184XA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110183V SG10202110183VA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110182P SG10202110182PA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
SG10202110181R SG10202110181RA (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (5) | US10239862B2 (fr) |
EP (2) | EP3949969A3 (fr) |
JP (1) | JP2020514419A (fr) |
KR (1) | KR20200031560A (fr) |
CN (1) | CN110612104A (fr) |
AU (1) | AU2018236272B2 (fr) |
BR (1) | BR112019019116A2 (fr) |
CA (1) | CA3055652A1 (fr) |
DK (1) | DK3595668T3 (fr) |
ES (1) | ES2894731T3 (fr) |
HU (1) | HUE056427T2 (fr) |
IL (1) | IL269283B2 (fr) |
MX (1) | MX2019010804A (fr) |
PT (1) | PT3595668T (fr) |
SG (5) | SG11201908131RA (fr) |
WO (1) | WO2018170179A1 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017202703A1 (fr) * | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide secondaire |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
CA3055652A1 (fr) | 2017-03-15 | 2018-09-20 | Silverback Therapeutics, Inc. | Composes de benzazepine, conjugues et utilisations associees |
CN112739713A (zh) | 2018-06-25 | 2021-04-30 | 华盛顿大学 | 有力的且选择性的白介素模拟物的从头设计 |
CN113164618A (zh) * | 2018-09-12 | 2021-07-23 | 希沃尔拜克治疗公司 | 用免疫刺激性缀合物治疗疾病的方法和组合物 |
WO2020056194A1 (fr) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Composés de benzazépine, conjugués et utilisations associées |
CN113166113A (zh) * | 2018-09-12 | 2021-07-23 | 希沃尔拜克治疗公司 | 取代的苯并氮杂䓬化合物、缀合物及其用途 |
US20220017588A1 (en) | 2018-11-20 | 2022-01-20 | University Of Washington | Split interleukin mimetics and their use |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
JP2022531454A (ja) * | 2019-05-08 | 2022-07-06 | メモリアル スローン ケタリング キャンサー センター | ムチン-16に対するヒト化抗体およびそれを使用する方法 |
US20200390899A1 (en) * | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
US20220315537A1 (en) * | 2019-06-13 | 2022-10-06 | Bolt Biotherapeutics, Inc. | Macromolecule-supported aminobenzazepine compounds |
MX2021015533A (es) | 2019-06-19 | 2022-02-10 | Silverback Therapeutics Inc | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. |
AU2020331036A1 (en) | 2019-08-15 | 2022-03-03 | Silverback Therapeutics, Inc. | Formulations of benzazepine conjugates and uses thereof |
WO2021067242A1 (fr) * | 2019-09-30 | 2021-04-08 | Bolt Biotherapeutics, Inc. | Immunoconjugués d'aminobenzazépine liés à des amides et leurs utilisations |
WO2021067644A1 (fr) * | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polythérapie comprenant des conjugués immunostimulants |
WO2021072330A1 (fr) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | CONJUGUÉS DE GALNAC ET D'UN INHIBITEUR DE TGFβR1 POUR LE TRAITEMENT DE MALADIES HÉPATIQUES |
WO2021072203A1 (fr) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Conjugués inhibiteur de tgfbetar1-anticorps anti-asgr et utilisations associées |
US11554999B2 (en) | 2019-11-15 | 2023-01-17 | Goodrich Corporation | Inflation systems for evacuation slides and life rafts |
WO2021168274A1 (fr) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
EP4121449A2 (fr) | 2020-03-16 | 2023-01-25 | Neoleukin Therapeutics, Inc. | Polypeptides de liaison au récepteur (beta)êta à l'interleukine-2 (il-2r(beta)) |
WO2021207207A2 (fr) | 2020-04-07 | 2021-10-14 | Neoleukin Therapeutics, Inc. | Leurres protéiques de novo de l'enzyme 2 de conversion de l'angiotensine (ace2) |
JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ,インク. | 抗asgr1抗体コンジュゲートおよびその使用 |
CA3187837A1 (fr) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Agents de liaison a cd47 et leurs utilisations |
EP4192884A1 (fr) * | 2020-08-04 | 2023-06-14 | Exelixis, Inc. | Agents de liaison à pd-l1 et leurs utilisations |
CN116234586A (zh) * | 2020-08-13 | 2023-06-06 | 博尔特生物治疗药物有限公司 | 吡唑并氮呯免疫缀合物及其用途 |
US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
CN117042806A (zh) * | 2021-03-08 | 2023-11-10 | 启德医药科技(苏州)有限公司 | 抗体-免疫激动剂缀合物及其应用 |
CA3215049A1 (fr) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Agents de liaison a folr1, conjugues de ceux-ci et leurs procedes d'utilisation |
TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Cd70結合劑、其結合物及其使用方法 |
WO2022242724A1 (fr) | 2021-05-19 | 2022-11-24 | 上海迪诺医药科技有限公司 | Composé contenant de l'azote, conjugué contenant ledit composé et utilisation associée |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023044318A2 (fr) | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Polypeptides de liaison au récepteur βêta à l'interleukine-2 (il-2rβ) |
WO2023154318A1 (fr) * | 2022-02-09 | 2023-08-17 | Bolt Biotherapeutics, Inc. | Immunoconjugués anti-trop2, aminobenzazépine et leurs utilisations |
CN117801107A (zh) * | 2022-09-30 | 2024-04-02 | 上海迪诺医药科技有限公司 | 苯并氮杂卓衍生物、含其的偶联物及其应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
EP0825186B1 (fr) | 1996-08-16 | 2002-04-17 | Pfizer Inc. | Dérivés de 2-aminobenzazépine et leur utilisation pour le traitement de l'immunosuppresion |
US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US7585326B2 (en) | 2004-08-06 | 2009-09-08 | Spinalmotion, Inc. | Methods and apparatus for intervertebral disc prosthesis insertion |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
TW201402124A (zh) * | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
RU2580320C2 (ru) | 2009-08-18 | 2016-04-10 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
US8691809B2 (en) | 2009-08-18 | 2014-04-08 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
ES2621874T3 (es) | 2010-03-26 | 2017-07-05 | Memorial Sloan-Kettering Cancer Center | Anticuerpos para MUC16 y métodos de uso de los mismos |
HUE052806T2 (hu) | 2010-12-06 | 2021-05-28 | Seagen Inc | LIV-1 elleni humanizált antitestek és azok alkalmazása a rák kezelésében |
CN106749023A (zh) | 2011-01-12 | 2017-05-31 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
US20140088085A1 (en) | 2011-01-12 | 2014-03-27 | Array Biopharma, Inc | Substituted Benzoazepines As Toll-Like Receptor Modulators |
WO2013033345A1 (fr) * | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulateurs et conjugués d'immunomodulateurs |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN106459055B (zh) * | 2014-01-27 | 2019-11-01 | 辉瑞大药厂 | 双功能细胞毒类药剂 |
RU2685259C2 (ru) | 2014-04-25 | 2019-04-17 | Пьер Фабр Медикамент | Конъюгат антитела и лекарственного средства и его применение для лечения рака |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
AU2015362720B2 (en) | 2014-12-16 | 2019-11-21 | Celgene Corporation | Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo(b)azepine-4-carboxamide, compositions thereof, and uses thereof |
JP6644792B2 (ja) | 2014-12-18 | 2020-02-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンザゼピンスルホンアミド化合物 |
ES2747386T3 (es) * | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
HUE042563T2 (hu) | 2015-03-06 | 2019-07-29 | Hoffmann La Roche | Benzazepin-dikarboxamid vegyületek |
US9943416B2 (en) | 2015-03-10 | 2018-04-17 | Simplify Medical Pty Limited | Intervertebral spacer that dynamically promotes bone growth |
CA3019396A1 (fr) | 2016-04-13 | 2017-10-19 | Siluria Technologies, Inc. | Couplage oxydant de methane pour la production d'olefines |
PL3453707T3 (pl) | 2016-05-06 | 2022-06-13 | Shanghai De Novo Pharmatech Co., Ltd. | Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie |
EP3464245B1 (fr) * | 2016-05-23 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide tertiaire |
WO2017202703A1 (fr) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide secondaire |
JP7012668B2 (ja) * | 2016-06-12 | 2022-02-14 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 |
WO2018140831A2 (fr) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Conjugués ciblant les tumeurs et leurs méthodes d'utilisation |
CA3049842A1 (fr) | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Compositions de produit de recombinaison-peptide et leurs methodes d'utilisation |
CA3055652A1 (fr) | 2017-03-15 | 2018-09-20 | Silverback Therapeutics, Inc. | Composes de benzazepine, conjugues et utilisations associees |
-
2018
- 2018-03-14 CA CA3055652A patent/CA3055652A1/fr active Pending
- 2018-03-14 SG SG11201908131R patent/SG11201908131RA/en unknown
- 2018-03-14 US US15/774,262 patent/US10239862B2/en active Active
- 2018-03-14 DK DK18767012.0T patent/DK3595668T3/da active
- 2018-03-14 JP JP2020500010A patent/JP2020514419A/ja not_active Ceased
- 2018-03-14 ES ES18767012T patent/ES2894731T3/es active Active
- 2018-03-14 CN CN201880030959.6A patent/CN110612104A/zh active Pending
- 2018-03-14 SG SG10202110184X patent/SG10202110184XA/en unknown
- 2018-03-14 SG SG10202110183V patent/SG10202110183VA/en unknown
- 2018-03-14 SG SG10202110182P patent/SG10202110182PA/en unknown
- 2018-03-14 HU HUE18767012A patent/HUE056427T2/hu unknown
- 2018-03-14 MX MX2019010804A patent/MX2019010804A/es unknown
- 2018-03-14 BR BR112019019116A patent/BR112019019116A2/pt unknown
- 2018-03-14 AU AU2018236272A patent/AU2018236272B2/en active Active
- 2018-03-14 KR KR1020197030167A patent/KR20200031560A/ko unknown
- 2018-03-14 SG SG10202110181R patent/SG10202110181RA/en unknown
- 2018-03-14 EP EP21179495.3A patent/EP3949969A3/fr active Pending
- 2018-03-14 PT PT187670120T patent/PT3595668T/pt unknown
- 2018-03-14 WO PCT/US2018/022510 patent/WO2018170179A1/fr unknown
- 2018-03-14 EP EP18767012.0A patent/EP3595668B1/fr active Active
- 2018-05-07 US US15/973,506 patent/US10519131B2/en not_active Expired - Fee Related
-
2019
- 2019-02-12 US US16/274,130 patent/US10428045B2/en active Active
- 2019-02-12 US US16/274,132 patent/US10442790B2/en active Active
- 2019-08-07 US US16/534,903 patent/US20200031798A1/en not_active Abandoned
- 2019-09-11 IL IL269283A patent/IL269283B2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201809982RA (en) | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201908743SA (en) | Methods and compositions for modulation of immune cells |